Recent News

• 03.18.2026 - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
• 03.10.2026 - Genprex to Participate at BIO Europe Spring 2026
• 02.23.2026 - Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
• 02.10.2026 - Genprex Announces IP Australia’s Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
• 01.07.2026 - Genprex Provides Clinical Update on Diabetes Gene Therapy Program
• 01.06.2026 - Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Recent Filings

• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.23.2026 - 8-K Current report
• 02.11.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.10.2026 - 8-K Current report
• 01.09.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 01.09.2026 - 8-K Current report
• 01.07.2026 - 8-K Current report
• 01.07.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 8-K Current report